Affimed NV (AFMD) Receives $5.15 Average Price Target from Brokerages

Shares of Affimed NV (NASDAQ:AFMD) have been given a consensus recommendation of “Buy” by the eight ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $5.15.

Several brokerages recently weighed in on AFMD. Zacks Investment Research raised shares of Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 price objective on the stock in a research report on Friday, March 29th. ValuEngine raised shares of Affimed from a “hold” rating to a “buy” rating in a research report on Wednesday, March 20th. Svb Leerink began coverage on shares of Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $8.00 price objective on the stock. Finally, Leerink Swann began coverage on shares of Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $4.17 price objective on the stock.

Shares of NASDAQ AFMD traded down $0.10 during mid-day trading on Friday, reaching $3.35. The company had a trading volume of 1,180,519 shares, compared to its average volume of 767,480. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.01 and a quick ratio of 3.00. The firm has a market capitalization of $209.01 million, a price-to-earnings ratio of -8.82 and a beta of 3.41. Affimed has a 12-month low of $1.40 and a 12-month high of $7.35.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The business had revenue of $25.96 million during the quarter. Affimed had a negative net margin of 87.00% and a negative return on equity of 44.56%. On average, analysts predict that Affimed will post -0.48 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of AFMD. FMR LLC bought a new position in Affimed during the third quarter valued at approximately $5,552,000. Keybank National Association OH bought a new position in Affimed during the fourth quarter valued at approximately $218,000. FDx Advisors Inc. bought a new position in Affimed during the fourth quarter valued at approximately $87,000. Lindbrook Capital LLC bought a new position in Affimed during the fourth quarter valued at approximately $38,000. Finally, Prescott Group Capital Management L.L.C. raised its position in Affimed by 16.1% during the fourth quarter. Prescott Group Capital Management L.L.C. now owns 190,680 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 26,480 shares in the last quarter. 41.06% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Recommended Story: Price-Sales Ratio

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.